Hinge Health CEO Daniel Perez sells 4,100 shares

Q: How many HNGE shares did Daniel Antonio Perez sell, and at what price?

Daniel Antonio Perez sold 4,100 Hinge Health, Inc. Class A common shares on October 6, 2026, at a weighted average price of $100.1978 per share. Reported sale prices ranged from $100.05 to $100.26 per share.

The reported Class A sale prices ranged from $100.05 to $100.26 per share, with a weighted average of $100.1978.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Hinge Health, Inc. CEO & Co-Founder, director and ten percent owner Daniel Antonio Perez converted 4,100 Class B shares into 4,100 Class A shares on October 6, 2026, then sold 4,100 Class A shares at a weighted average $100.1978 per share. The sale was made under a Rule 10b5-1 plan adopted by Perez and his spouse on June 11, 2026. Following the transaction, Perez reported 9,774,572 Class B shares, excluding 3,777,002 performance-based restricted stock units. His spouse separately held 208,445 Class B shares and 35,470 Class A shares indirectly.

Insider Trade Summary 10b5-1

Exercise and sale activity reported; no spread calculated

Exercise and Sale 5 txns

Insider Perez Daniel Antonio

Role CEO & Co-Founder

Sold 4,100 shs ($411K)

Approx. gross sale proceeds $411K

Type	Security	Shares	Price	Value
Conversion	Class B Common Stock ^{F3, F4}	4,100	$0.00	$0.00
Conversion	Class A Common Stock	4,100	$0.00	$0.00
Sale	Class A Common Stock ^{F1, F2}	4,100	$100.1978	$411K
holding	Class B Common Stock ^F3	--	--	--
holding	Class A Common Stock	--	--	--

Holdings After Transaction: Class B Common Stock — 9,774,572 contracts (Direct); Class A Common Stock — 0 shares (Direct); Class B Common Stock — 208,445 contracts (Indirect, By Spouse); Class A Common Stock — 35,470 shares (Indirect, By Spouse)

Footnotes (4)

F1. The sales reported in this line item were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and his spouse on June 11, 2026.
F2. Represents the weighted average sale price. The lowest price at which shares were sold was $100.05 and the highest price at which shares were sold was $100.26. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.
F3. Each share of Class B Common Stock is convertible into one share of the lssuer's Class A Common Stock at any time, at the election of the holder or automatically upon certain transfers, whether or not for value, or upon the occurrence of certain events or conditions described in the Issuer's Amended and Restated Certificate of Incorporation.
F4. Excludes 3,777,002 performance-based restricted stock units held by the Reporting Person.

Key Figures

Class B-to-Class A conversion: 4,100 Class B shares into 4,100 Class A shares Class A shares sold: 4,100 shares Weighted average sale price: $100.1978 per share +3 more

6 metrics

Class B-to-Class A conversion 4,100 Class B shares into 4,100 Class A shares October 6, 2026

Class A shares sold 4,100 shares October 6, 2026

Weighted average sale price $100.1978 per share Class A shares sold October 6, 2026

Reported sale price range $100.05 to $100.26 per share Class A shares sold October 6, 2026

Class B shares following transaction 9,774,572 shares Reported after the October 6, 2026 transaction; excludes 3,777,002 performance-based restricted stock units

Indirect holdings by spouse 208,445 Class B shares and 35,470 Class A shares Reported October 6, 2026

Key Terms

Rule 10b5-1 trading plan, weighted average sale price, performance-based restricted stock units

3 terms

Rule 10b5-1 trading plan regulatory

"effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average sale price financial

"Represents the weighted average sale price"

performance-based restricted stock units financial

"3,777,002 performance-based restricted stock units"

Performance-based restricted stock units are a type of employee equity award that converts into company shares only if predefined financial or operational targets are met over a set period. Think of it like a bonus check that becomes stock only when specific goals are hit; it ties pay to results, aligning managers’ incentives with shareholders. Investors care because these awards affect future share count, executive incentives, and signal how management’s success will be measured and rewarded.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many HNGE shares did Daniel Antonio Perez sell, and at what price?

Daniel Antonio Perez sold 4,100 Hinge Health, Inc. Class A common shares on October 6, 2026, at a weighted average price of $100.1978 per share. Reported sale prices ranged from $100.05 to $100.26 per share.

How does HNGE Class B stock convert to Class A?

Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the holder’s election or automatically upon certain transfers, whether or not for value, or upon certain events or conditions described in the company’s Amended and Restated Certificate of Incorporation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 10/07/2026 - 09:58 PM EDT Accepted by SEC EDGAR 10/07/2026 - 09:57 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Perez Daniel Antonio

(Last)

(First)

(Middle)

C/O HINGE HEALTH, INC.

455 MARKET STREET, SUITE 700

(Street)

SAN FRANCISCO

CALIFORNIA

94015

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Hinge Health, Inc. [ HNGE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	CEO & Co-Founder

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/06/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Class A Common Stock	10/06/2026		C		4,100	A	$0	4,100	D
Class A Common Stock	10/06/2026		S⁽¹⁾		4,100	D	$100.1978⁽²⁾	0	D
Class A Common Stock								35,470	I	By Spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Class B Common Stock	⁽³⁾	10/06/2026		C			4,100	⁽³⁾	⁽³⁾	Class A Common Stock	4,100	$0	9,774,572⁽⁴⁾	D
Class B Common Stock	⁽³⁾							⁽³⁾	⁽³⁾	Class A Common Stock	208,445		208,445	I	By Spouse

Explanation of Responses:

1. The sales reported in this line item were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and his spouse on June 11, 2026.

2. Represents the weighted average sale price. The lowest price at which shares were sold was $100.05 and the highest price at which shares were sold was $100.26. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

3. Each share of Class B Common Stock is convertible into one share of the lssuer's Class A Common Stock at any time, at the election of the holder or automatically upon certain transfers, whether or not for value, or upon the occurrence of certain events or conditions described in the Issuer's Amended and Restated Certificate of Incorporation.

4. Excludes 3,777,002 performance-based restricted stock units held by the Reporting Person.

	/s/ Mahnaz Dodge, Attorney-in-Fact	10/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR